197 related articles for article (PubMed ID: 32234883)
1. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract][Full Text] [Related]
2. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance.
Brodaczewska KK; Bielecka ZF; Maliszewska-Olejniczak K; Szczylik C; Porta C; Bartnik E; Czarnecka AM
Oncol Rep; 2019 Nov; 42(5):1878-1892. PubMed ID: 31545459
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
[TBL] [Abstract][Full Text] [Related]
5. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
6. P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Sekino Y; Takemoto K; Murata D; Babasaki T; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Taniyama D; Shigeta M; Kuraoka K; Mita K; Kaneko M; Sentani K; Oue N; Teishima J
Anticancer Res; 2021 Sep; 41(9):4287-4294. PubMed ID: 34475048
[TBL] [Abstract][Full Text] [Related]
7. A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.
Chen YL; Ge GJ; Qi C; Wang H; Wang HL; Li LY; Li GH; Xia LQ
J Cell Physiol; 2018 Oct; 233(10):6649-6660. PubMed ID: 29327492
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
9. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
10. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
11. Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Park I; Cho YM; Lee JL; Ahn JH; Lee DH
Tumour Biol; 2016 Apr; 37(4):4919-27. PubMed ID: 26526582
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Buchler T; Klapka R; Melichar B; Brabec P; Dusek L; Vyzula R; Abrahamova J
Ann Oncol; 2012 Feb; 23(2):395-401. PubMed ID: 21536664
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
15. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
16. CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Sekino Y; Takemoto K; Murata D; Babasaki T; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Taniyama D; Shigeta M; Kuraoka K; Mita K; Kaneko M; Sentani K; Oue N; Teishima J
Anticancer Res; 2021 Oct; 41(10):4875-4883. PubMed ID: 34593435
[TBL] [Abstract][Full Text] [Related]
17. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
18. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
20. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
